<DOC>
	<DOCNO>NCT00014469</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness busulfan melphalan follow donor bone marrow transplantation treat patient advanced hematologic cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Bone Marrow Transplantation Treating Patients With Advanced Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine antileukemic potential busulfan melphalan prior allogeneic bone marrow transplantation patient advance high-risk hematologic malignancy . - Determine incidence transplantation-related morbidity mortality patient treat regimen . - Determine incidence acute chronic graft-versus-host disease patient treat regimen . OUTLINE : Patients receive cytoreductive chemotherapy comprise busulfan IV 2 hour every 6 hour total 16 dos day -8 -5 melphalan IV 30 minute day -4 -2 . Patients undergo T-cell replete allogeneic bone marrow transplantation day 0 . For graft-versus-host disease prophylaxis , patient receive tacrolimus IV continuously every 12 hour begin day -1 continue 50 day 6 month follow taper . Once oral medication tolerate , patient switch oral tacrolimus every 12 hour . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 . Patients follow weekly day 100 , every 6 week 3 month , every 3 month 1 year , every 3-6 month 6 month . PROJECTED ACCRUAL : A maximum 30 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one following : Infant leukemia Acute lymphoblastic leukemia 3rd great remission relapse Undifferentiated biphenotypic leukemia 2nd great remission relapse Juvenile chronic myelogenous leukemia ( CML ) Acute myelogenous leukemia ( AML ) 3rd great remission relapse Primary advance myelodysplastic syndrome ( MDS ) exclude refractory anemia ( RA ) RA ring sideroblast Therapyrelated MDS stage AML CML 2nd great chronic phase , accelerate , blastic phase Acute leukemia , CML , MDS unable tolerate total body irradiation ( TBI ) due potential neurotoxicity ( prior TBI , prior local radiotherapy , 2 year age ) No active CNS disease Related unrelated bone marrow donor match HLAA , B , DR beta 1 PATIENT CHARACTERISTICS : Age : Under 60 ( 60 consider casebycase basis ) Performance status : Karnofsky 70100 % Lansky 70100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : AST ALT less 2 time upper limit normal Bilirubin le 1.5 mg/dL unless liver involved disease Renal : Creatinine normal Creatinine clearance great 60 mL/min Cardiovascular : Asymptomatic prior risk factor OR LVEF great 50 % symptomatic Pulmonary : Asymptomatic prior risk factor OR Diffusion capacity great 50 % predict ( correct hemoglobin ) symptomatic Other : No active uncontrolled viral , bacterial , fungal infection Not pregnant nursing Negative pregnancy test HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : More 6 month since prior allogeneic autologous stem cell transplantation Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>